Opto-Microfluidics: A Rapid and Sensitive Platform for Biological Diagnostics

点击翻译按钮获取中文摘要

One in four people above 25 years suffer from diabetes-related diseases in Australia, with an associated economic cost exceeding $3 billion a year. A microdevice for continuous glucose monitoring would help patients to manage the disease, leading to huge individual, clinical and societal benefits. Life expectancy is expected to increase along with quality of life. Integration of the microdevice with insulin delivery would realise an 'artificial pancreas', revolutionising the management and treatment of the disease. The technology will also provide a platform for other point-of-care medical diagnostic devices, which will allow early participation in this emerging market and cement Australia's position in bionanotechnology.